Lupin appoints Nicholas Hart as President – Specialty for US Business
He has over 25 years of experience in specialty business, strategic and commercial operations
Author
Barriers impede biosimilar market entry into the US despite BPCIA: GlobalData
There are only nine biosimilars available on the US market to date and it is estimated that only three per cent of spending on…
Glenmark gets ANDA approval for Colesevelam Hydrochloride Tablets, 625 mg
The company has already commenced supplies of the product to the US market
Patients First!
Currently less than 1.3 per cent of clinical trials conducted in the world are in India. There is a need to ensure more drug…
Lupin launches Corcal Bone and Beauty supplement
Corcal Bone and Beauty is available in packs of 10 mini-tablets
Epygen plans to raise Rs 300 cr to propel biosimilars in India
The funds will be utlilised for clinical trials of pipeline molecules and securing IP for technologies for novel biological…
Glenmark Pharma to present updated info on GBR 830 at International Investigative Dermatology…
GBR 830 is a first-in-class, investigational, anti-OX40 monoclonal antibody for treatment of moderate-to-severe atopic dermatitis
Annual Opex in Pharma Summit to be held in Mumbai
The event will discuss on how pharma manufacturers should efficiently implement excellence initiatives
Cipla partners with MannKind for Afrezza – inhaled insulin
Signs deal for exclusive marketing and distribution of the only US FDA approved inhaled insulin
AstraZeneca sells Seroquel rights to Luye Pharma for $538 mn
It is used for the treatment of schizophrenia and bipolar disease